The new era of precision medicine in hepatocellular carcinoma:the urgent need for promising biomarkers

作     者：Haruhiko Takeda Hiroki Nishikawa Yukio Osaki 

作者机构：Department of Gastroenterology and HepatologyGraduate School of MedicineKyoto UniversityKyotoJapan Department of Gastroenterology and HepatologyOsaka Red Cross HospitalOsakaJapan Department of Gastroenterology and HepatologyHyogo College of MedicineNishinomiyaJapan Department of Gastroenterology and HepatologyMeiwa HospitalNishinomiyaJapan 

出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)

年 卷 期：2018年第7卷第6期

页      面：490-491页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：prognosis carcinoma hepatocellular 

摘      要：Hepatocellular carcinoma(HCC)is the second most lethal malignancy worldwide,and the prognosis of advanced HCC is especially *** the SHARP trial reported in 2007,a number of phase III trials of molecular targeting agents for advanced HCC have been conducted,but most of them have failed to achieve their primary endpoint,and sorafenib has been the only first-line systemic therapy approved for HCC in this decade(1).